Claims
- 1. A hydrogel forming system which comprises hydrophobic and hydrophilic components which are convertible into a one phase crosslinked network structure by free radical polymerization.
- 2. A hydrogel-forming system which comprises from 0.01 to 99.99% by weight of (A) a hydrophobic macromer with unsaturated group terminated ends, and from 99.99 to 0.01% by weight of (B) a hydrophilic polymer which is a polysaccharide containing hydroxy groups which are reacted with unsaturated group introducing compound; wherein the total of the percentages of (A) and (B) is 100%.
- 3. The hydrogel-forming system according to claim 2 wherein the hydrophobic macromer is prepared by reacting the hydroxyls of a diol obtained by converting hydroxy of terminal carboxylic acid group of aliphatic polyester to aminoethanol group, with an unsaturated group introducing compound.
- 4. The hydrogel-forming system according to claim 2 wherein the hydrophilic polymer is dextran wherein one or more hydroxyls in a glucose unit of the dextran is (are) reacted with an unsaturated group introducing compound.
- 5. The hydrogel-forming system according to claim 2 wherein the hydrophillic polymer is dextran-maleic acid monoester.
- 6. Hydrogel formed by the free radical polymerization of the hydrogel-forming system of claim 2 which has a three dimensional crosslinked polymer network structure containing hydrophobic and hydrophilic components.
- 7. Hydrogel as claimed in claim 6 which has a drug of weight average molecular weight ranging from 200 to 1,000 entrapped in the three dimensional crosslinked polymer network.
- 8. The hydrogel as claimed in claim 7 wherein the drug entrapped in the three dimensional network is indomethacin.
- 9. Hydrogel as claimed in claim 6 which has a water-soluble macromolecule of weight average molecular weight ranging from 1,000 to 10,000 entrapped in the three dimensional crosslinked polymer network.
- 10. The hydrogel as claimed in claim 9 wherein the water-soluble macromolecule is a polypeptide.
- 11. The hydrogel as claimed in claim 10 wherein the polypeptide is insulin.
- 12. Hydrogel as claimed in claim 6 which has a synthetic or natural polymer of weight average molecular weight ranging from 10,000 to 100,000 entrapped in the three dimensional crosslinked polymer network.
- 13. The hydrogel as claimed in claim 12 wherein the synthetic or natural polymer is a protein.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of U.S. Provisional Application No. 60/128,803, filed Apr. 12, 1999.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60128803 |
Apr 1999 |
US |
Divisions (3)
|
Number |
Date |
Country |
Parent |
10369676 |
Feb 2003 |
US |
Child |
10733291 |
Dec 2003 |
US |
Parent |
10096435 |
Mar 2002 |
US |
Child |
10369676 |
Feb 2003 |
US |
Parent |
09531451 |
Mar 2000 |
US |
Child |
10096435 |
Mar 2002 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09531451 |
Mar 2000 |
US |
Child |
10096435 |
Mar 2002 |
US |